Hutchmed's Savolitinib Combined with Tagrisso: NDA Submitted to U.S. FDA
nashnova research
AstraZeneca has filed an NDA with the U.S. FDA for savolitinib (Orpathys®) combined with osimertinib (Tagrisso®), targeting late-stage NSCLC patients whose tumors progressed on EGFR therapy with MET overexpression — a key step from China approval toward U.S. commercialization.
What problem does this filing address?
Patients with non-small cell lung cancer often develop resistance after treatment with third-generation EGFR drugs such as Tagrisso®. MET overexpression or amplification is one of the most common resistance mechanisms.
This means → the original drug stops working because the tumor finds a new growth pathway, and patients currently fall back to chemotherapy with very limited options.
Savolitinib — a MET inhibitor — combined with Tagrisso® aims to block both the EGFR and MET pathways at once, sparing patients from returning to chemo.
What do the clinical data show?
The filing is supported by the SAFFRON global Phase III trial, which compared the combination against standard platinum-based doublet chemotherapy.
The combination achieved statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS).
In plain terms = compared with chemo, this oral combination kept tumors from worsening longer and extended patients' lives, with no new safety concerns. Full data will be presented at the 2026 ESMO Congress presidential symposium.
What does this mean for HUTCHMED?
Savolitinib was co-developed by AstraZeneca and HUTCHMED (和黄医药). AstraZeneca handles commercialization.
This means → HUTCHMED earns milestone payments and royalties rather than building its own U.S. sales force, but the FDA review outcome directly determines whether that revenue materializes.
The combination was already approved in China based on the SACHI Phase III study. This NDA filing marks the critical inflection from a single-country approval to global commercialization.
市场有风险，内容仅供研究参考，不构成投资建议。